IVGN Invitrogen (MM)

Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, announced the global launch of its updated GIBCO cell culture media bottles. The new bottle design has an angled neck for easier pipetting and pouring; compact form for improved handling and storage; and a wider mouth to reduce the chance of contact with the pipette. �We invested significant thought and energy into redesigning the GIBCO bottles, carefully observing how bench scientists work in cell culture,� said Nicolas Barthelemy, Senior Vice President, Cell Systems Division for Invitrogen. �These new bottles highlight our commitment to innovating products and services that create better lab experiences and better results for our customers.� Working with IDEO, a leading innovation and design firm, Invitrogen utilized in-lab fieldwork observations to shed light on how cell culture scientists use current media bottles in their daily workflow. The bottle was designed with direct input from researchers throughout the entire development process to ensure maximum efficiency and ease of use. The key features of the new bottle provide solutions to the challenges observed during field research with customers: improved ergonomics of the �under-the-hood� workflow; superior handling and storage; easier identification and additional room for supplements. �We have designed the new GIBCO bottle with the scientist and lab process in mind at all times,� said Todd Laird, Vice President and General Manager of Invitrogen�s Cell Culture Essentials. �The result is a bottle with a fresh look and novel form that positively affects lab efficiency and reduces errors.� The new bottle requires no adjustment in day-to-day cell culture practices and can be quickly integrated to optimize work under cell culture hoods. For more information on the redesign, please visit www.invitrogen.com/gibcobottle. About Invitrogen Invitrogen Corporation (NASDAQ:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, stem cells, cell therapy and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company employs approximately 4,700 scientists and other professionals and had revenues of approximately $1.3 billion in 2007. For more information, visit www.invitrogen.com. Safe Harbor Statement Certain statements contained in this press release are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and it is Invitrogen's intent that such statements be protected by the safe harbor created thereby. Forward looking statements include, but are not limited to; 1) the bottle requires no adjustment in day-to-day cell culture practices; 2) the bottle can be quickly integrated to optimize work under cell culture hoods. Potential risks and uncertainties include, but are not limited to; a) the bottle may or may not positively affect lab efficiency and reduce errors; and the risks that the market will not accept the companies� products and services, or that the companies will be unsuccessful in their efforts to develop new products and services, as well as other risks and uncertainties detailed from time to time in Invitrogen's Securities and Exchange Commission filings.